ALX Oncology Holdings (ALX Oncology Holdings) Shares Outstanding (Basic Average)

: 49.06 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ALX Oncology Holdings's average basic shares outstanding for the quarter that ended in Dec. 2023 was 49.06 Mil.

ALX Oncology Holdings Shares Outstanding (Basic Average) Historical Data

The historical data trend for ALX Oncology Holdings's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Shares Outstanding (Basic Average)

Get a 7-Day Free Trial

21.95

18.49

40.31

40.70

42.99

ALX Oncology Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Shares Outstanding (Basic Average)	Get a 7-Day Free Trial															40.75	40.86	40.88	41.15	49.06

ALX Oncology Holdings Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

ALX Oncology Holdings (NAS:ALXO) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

ALX Oncology Holdings Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Shares Outstanding (Basic Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia	officer: Chief Financial Officer	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph	officer: Chief Medical Officer	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S	director, 10 percent owner, other: Executive Chairman	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani	director	3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke	officer: VP Fin & Chief Acct Officer	C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538